Michael Popov

Michael Popov practices at Medtrans Behavioral Nevada Casal in Las Vegas, Nevada.

Michael Popov's NPI, 1518351097, was assigned on March 24, 2015. Michael Popov holds Nevada license DO2507.

Michael Popov's primary practice is Medtrans Behavioral Nevada Casal, at 4270 S Decatur Blvd, Las Vegas, NV 89103 in Clark County. The practice phone is (775) 538-6700.

Michael Popov's primary practice is Medtrans Behavioral Nevada Casal in Las Vegas, Nevada. The medical group on file is Medtrans Behavioral Nevada Casal, PLLC. Dmand AI also links Michael Popov to 4 more group practices and clinics and 3 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Michael Popov practices, 4 sites in all. Vendor and product names are available with a free account.

Psychiatry is Michael Popov's primary specialty in the NPI Registry, under taxonomy code 2084P0800X. Michael Popov is licensed in Nevada.

CMS data shows 758 Medicare services from Michael Popov across 6 procedure codes in 2024, for 74 Medicare patients. Medicare paid $71,049 for them. Every service was in an office.

CMS counts 74 Medicare patients who saw Michael Popov in 2024. The largest group is 65 to 74, with 39 patients. 75% of them have anxiety, and 75% have depression. 39% are also on Medicaid. Their average risk score is 1.20, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Michael Popov's median patient age at 44, with 60% women.

In 2024, Michael Popov wrote 675 Medicare Part D claims for 49 patients. 87% of them were for generic drugs. CMS names the drug for 546 of them, across 22 drugs with 11 or more claims each, at $164,035 in total drug cost. In 2023, CMS named 560 claims across 24 drugs.

Michael Popov accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Michael Popov as offering telehealth.

CMS Open Payments shows 341 general payments to Michael Popov from 23 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 99% of the total. Neurocrine BioSciences, Inc. paid the most, $2,484.